TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient interview with University of British Columbia researcher Cheryl Wellington describes how cholesterol may affect brain health through both blood-vessel disease and processes inside the brain. Wellington said high LDL in midlife is associated with an estimated 7% to 9% increase in Alzheimer’s and related dementia risk, but the interview does not establish that lowering cholesterol prevents dementia for an individual.
Researcher Cheryl Wellington says cholesterol may affect brain health through more than one route, including blood-vessel disease and processes within the brain, and that high LDL in midlife is associated with an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias. See also whether lowering cholesterol can prevent or treat Alzheimer’s. In an interview published by Being Patient, the University of British Columbia professor discussed how cholesterol and ApoE may relate to amyloid clearance and inflammation; the discussion does not show that cholesterol treatment prevents Alzheimer’s disease.
Wellington explained that cholesterol circulating in the blood and cholesterol within the brain are not interchangeable pools. The blood-brain barrier limits movement between them, she said, meaning that blood cholesterol does not simply pass into brain tissue. Cholesterol nevertheless has functions on both sides of that barrier, and changes in blood vessels can affect the brain’s health.
In the interview, Wellington linked high LDL—often called “bad” cholesterol—with atherosclerosis, the buildup of plaque in blood vessels. Plaque can affect vessels supplying the brain and may occur alongside Alzheimer’s-related changes, she said. She also described amyloid plaques as a separate process: these are deposits involving amyloid-beta, a peptide produced in the brain. The interview notes that amyloid-beta is normally cleared through drainage pathways that include blood vessels.
Wellington also discussed research into cholesterol handling by brain immune cells and the role of ApoE, a protein involved in transporting cholesterol, including genes that may protect against APOE4 Alzheimer’s risk. She said cholesterol buildup in these cells may contribute to inflammation, particularly for people carrying the ApoE4 variant. These mechanisms are presented as areas of research, not as proof that any one pathway causes Alzheimer’s in a particular person.
How LDL May Affect Brain Health
The discussion matters because it places cholesterol among several factors that can shape brain and vascular health, rather than treating dementia risk as a process isolated from the rest of the body. Blood-vessel disease can impair circulation, while brain-specific cholesterol handling may relate to inflammation and the handling of amyloid-beta. Those are distinct biological routes, even if they may intersect in people with Alzheimer’s pathology.
Wellington said bringing LDL into a healthy range may reduce Alzheimer’s and other dementia risk. That statement should be read as a population-level risk claim, not a guarantee that cholesterol-lowering treatment will prevent dementia. The interview supplies no study design, participant details, or treatment results behind the 7% to 9% estimate, so readers should not interpret it as an individual prediction or a treatment effect.
For readers, the practical implication is that cholesterol remains a health measure worth discussing with a clinician, including in midlife. Decisions about testing or treatment depend on a person’s broader health and should be made with a qualified professional. The material does not recommend a specific drug, target level, or treatment plan for Alzheimer’s prevention.
Products Worth Considering
Philips Hue Bridge Pro Starter Kit with 4 A19 E26 Smart Bulbs
Philips Hue Starter Kit with Bridge Pro and 4 Retrofit LED Recessed Downlights
Arlo Pro Wireless Security Camera, 2K HDR, 6th Gen, 4-Camera Kit
As an affiliate, we earn on qualifying purchases.
Blood Cholesterol and Brain Cholesterol
The Being Patient item is a conversation between founder Deborah Kan and Wellington, a professor and vice chair of research in the University of British Columbia’s Department of Pathology and Laboratory Medicine. Wellington studies cholesterol and proteins involved in its transport, including ApoE, in relation to brain health and Alzheimer’s risk. The article says the live talk was produced with support from NewAmsterdam Pharma and that the sponsor had no role in guest selection, questions, or prepublication review.
The distinction between blood and brain cholesterol is central to the interview. Because the blood-brain barrier restricts direct exchange, researchers consider both vascular cholesterol and cholesterol processes inside brain tissue. The interview also distinguishes atherosclerotic plaque in blood vessels from amyloid plaques in the brain; the shared word “plaque” should not obscure that these are different deposits.
““There is something called the blood-brain barrier that’s kind of like a wall.””
— Cheryl Wellington, professor and vice chair of research at the University of British Columbia
Limits of the Risk Estimate
The supplied interview does not identify the research behind the 7% to 9% estimate, including whether it refers to relative or absolute risk, the population studied, or the time period measured. It also does not provide evidence that lowering LDL by a specified amount prevents Alzheimer’s, or quantify how much any treatment might alter a person’s risk.
The mechanisms involving amyloid-beta clearance, brain immune cells, inflammation, and ApoE4 are discussed as research findings or possibilities. The material does not establish that cholesterol buildup in immune cells causes Alzheimer’s, nor that people with ApoE4 will develop the disease. It also does not give a specific cholesterol threshold or explain how risks vary by age, existing conditions, or treatment history.
What Research and Clinicians Must Clarify
The interview does not announce a new trial, policy, or clinical guideline, and it gives no forthcoming research milestone. Further evidence would need to clarify the source and meaning of the risk estimate, distinguish the effects of blood-vessel health from brain cholesterol processes, and test whether cholesterol-lowering interventions change dementia outcomes over time.
For now, Wellington’s practical message is to check LDL and discuss results with a physician. The source does not offer a dementia-specific treatment recommendation. People considering cholesterol medication or changes to existing care should consult a qualified health professional, who can assess their individual circumstances.
Key Questions
Does blood cholesterol enter the brain?
Wellington said the blood-brain barrier limits direct movement of cholesterol from the bloodstream into the brain. Blood cholesterol and cholesterol within brain tissue are therefore considered separate, though both may affect neurological health.
What did the interview say about high LDL and dementia risk?
Wellington described high LDL in midlife as associated with an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias. The supplied material does not state the estimate’s comparison group, time window, or whether it is relative or absolute risk.
Does lowering cholesterol prevent Alzheimer’s disease?
The interview says that bringing LDL into range may reduce risk, but it does not establish that treatment prevents Alzheimer’s for an individual or provide a treatment effect. Discuss cholesterol testing and treatment decisions with a qualified clinician.
How are ApoE4 and brain cholesterol connected?
Wellington discussed research suggesting cholesterol buildup in brain immune cells may contribute to inflammation, particularly among people with the ApoE4 variant. The interview does not establish this as a proven cause of Alzheimer’s or say that every ApoE4 carrier will develop the disease.
Source: beingpatient.com
